In addition, the company identified a new, undi
Post# of 30028
Posted On: 01/15/2015 8:44:45 PM
Quote:
In addition, the company identified a new, undisclosed biomarker that correlates with AD diagnosis in the LP-002 study (p<0.0001). This new marker could become a central component of a multivariate algorithm (LymPro Score) that is currently being analyzed by company scientists to deliver a simplified assessment of an individual's likelihood of having Alzheimer's disease.
Yes, it is a newly discovered bio marker that would compliment and enhance the multivariate numbers, to be announced...
http://ir.amarantus.com/company-news/detail/1...alzheimers
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼